Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions

Lesions of the common inflammatory skin disease psoriasis are characterized by epidermal hyperproliferation, leucocyte adhesion molecule expression and leucocyte infiltration. The local release of proinflammatory cytokines. such as TNF‐α, may play an important role in the induction of these events. We have, therefore, analysed aqueous extracts of lesional and uninvolved (clinically normal) stratum corneum for the presence of TNF‐α immunoreactivity and biological activity. TNF‐α immunoreactivity and bioactivity were consistently higher in lesional compared with uninvolved samples. By using an anti‐TNF‐α neutralizing antibody it was demonstrated that the biological activity measured was due to the presence of TNF‐α alone. Concentrations of soluble TNF receptors (p55 and p75) were also higher in lesional stratum corneum extracts, with the p55 form predominating. The plasma of psoriatic patients was also found to contain elevated concentrations of soluble p55 compared with normal controls. These results confirm the presence of immunoreactive TNF‐α and, for the first time, conclusively demonstrate TNF‐α biological activity and quantifiable concentrations of soluble TNF receptors (p55 and p75) in lesional psorialic samples. TNF‐α recovery from stratum corneum probably reflects synthesis in deeper, viable layers, where il is likely lo exert its biological effects. Local and systemic release of soluble TNF receplors, in particular p55, may serve to regulate the effects of TNF‐α in psoriasis.

[1]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[2]  G. Adolf,et al.  Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. , 1992, Cytokine.

[3]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[4]  I. Colditz,et al.  The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. , 1992, Immunology.

[5]  M. Wadhwa,et al.  Cytokines in skin lesions of psoriasis. , 1990, Cytokine.

[6]  S. Akira,et al.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  D. Macdonald,et al.  Endothelial leucocyte adhesion molecule‐1 (ELAM‐1) expression in cutaneous inflammation , 1991, The British journal of dermatology.

[8]  A. Meager,et al.  Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). , 1987, Hybridoma.

[9]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[10]  F. Balkwill,et al.  Tumour necrosis factor. , 1989, British medical bulletin.

[11]  D. I. Stuart,et al.  Structure of tumour necrosis factor , 1989, Nature.

[12]  D. Macdonald,et al.  Cutaneous lymphocyte trafficking in the inflammatory dermatoses , 1992, The British journal of dermatology.

[13]  A. Meager,et al.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.

[14]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  James T. Elder,et al.  Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. , 1991, The American journal of pathology.

[16]  A. Mantovani,et al.  Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. , 1987, Journal of immunology.

[17]  D. de Silva Tumour necrosis factor , 1990, The Ceylon medical journal.

[18]  J. Voorhees,et al.  Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. , 1989, Journal of the American Academy of Dermatology.

[19]  U. Gullberg,et al.  Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. , 1992, European journal of cell biology.

[20]  D. Wallach,et al.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. , 1991, Cancer research.